Table 1

Baseline characteristics of patients in sDMARD and TNFi cohorts

sDMARD; n=3058TNFi; n=11 200
Mean age, years (SD)59.5 (12.5)55.6 (12.3)
Female, %7578
Median disease duration, years (IQR)6 (1, 15)11 (6, 19)
Mean DAS28 (SD)5.3 (1.1)6.6 (1.0)
Mean HAQ score (SD)1.5 (0.7)2.0 (0.6)
Proportion of patients who received ≥4 sDMARDs prior to study registration, %2153
Proportion of patients who received methotrexate prior to study registration, %8297
Recruited before 30 June 2004, %1951
Hypertension, %3028
Diabetes, %65
Chronic lung disease, %1913
Current/previous smoker, %6259
Glucocorticoid, %2244
NSAID/COX-2 inhibitor therapy, %5663
Antiplatelet therapy, %75
Statin therapy, %95
  • COX, cyclooxygenase inhibitor; DAS28, disease activity in 28 joints; HAQ score, health assessment questionnaire score; NSAID, non-steroidal anti-inflammatory drugs; sDMARD, synthetic disease-modifying antirheumatic drug; TNFi, tumour necrosis factor α inhibitor.